Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Teva's Copaxone progresses toward FDA approval

Aug. 9, 1996

5-HT1A agonist with alpha1-adrenoceptor-blocking properties from Byk Gulden

Aug. 9, 1996

Multiuse melatonergic 3-alkoxybenzylpiperidine derivatives from Bristol-Myers Squibb

Aug. 9, 1996

ADIR describes compunds with high affinity for 5-HT2C and/or 5-HT3C receptors

Aug. 9, 1996

Lidocaine nasal drops shown effective for fast migraine pain relief

Aug. 9, 1996

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Menarini and Lilly sign comarketing agreement

Aug. 9, 1996

Bifemelane claimed for cerebrovascular disorders treatment

July 26, 1996

Research supports role of testosterone in pathogenesis of stroke

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...